SCHEMBL6849558

SCHEMBL6849558

O=C(CCc1ccc(Cl)cc1)NCC1CCc2c(ncn2C(c2ccccc2)(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 5/20 0.41
LTA4H P09960 4/20 0.40
EPHX2 P34913 2/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
FAAH O00519 2/20 0.38
BCHE P06276 2/20 0.38
ACHE P22303 2/20 0.38
MAOB P27338 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6849769 0.95 CCR2 (0.43) CCR2LTA4HEPHX2FAAHBCHE
SCHEMBL6849628 0.93 CCR2 (0.41) CCR2LTA4HEPHX2KDM4EALDH1A1
SCHEMBL6846987 0.91 CCR2 (0.41) CCR2KDM4EALDH1A1HPGDFAAH
SCHEMBL6851333 0.84 CCR2 (0.41) CCR2KDM4EFAAHBCHEACHE
SCHEMBL6852753 0.74 CHRM3 (0.33)
SCHEMBL6851029 0.73 LMNA (0.41) ALDH1A1MEN1KMT2AMAPT
SCHEMBL6851432 0.73 P2RX7 (0.38) CCR2LTA4HKDM4EALDH1A1HPGD
SCHEMBL7615123 0.73 CCR2 (0.39) CCR2LTA4HEPHX2KDM4EALDH1A1
SCHEMBL6846766 0.72 CHRM3 (0.33)
SCHEMBL6963804 0.70 SIGMAR1 (0.41) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 CCR2 707/4885LTA4H 415/4885EPHX2 1125/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 CCR2 707/4885LTA4H 415/4885EPHX2 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.